These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20141502)

  • 1. Evaluation and modeling of the eutectic composition of various drug-polyethylene glycol solid dispersions.
    Baird JA; Taylor LS
    Pharm Dev Technol; 2011 Jun; 16(3):201-11. PubMed ID: 20141502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting the formation of eutectic solid dispersions and their dissolution behavior.
    Vippagunta SR; Wang Z; Hornung S; Krill SL
    J Pharm Sci; 2007 Feb; 96(2):294-304. PubMed ID: 17051588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the microstructure of semicrystalline solid dispersions.
    Zhu Q; Taylor LS; Harris MT
    Mol Pharm; 2010 Aug; 7(4):1291-300. PubMed ID: 20550195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation and characterization of gliclazide-polyethylene glycol 4000 solid dispersions.
    Patil MP; Gaikwad NJ
    Acta Pharm; 2009 Mar; 59(1):57-65. PubMed ID: 19304558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization and stability of solid dispersions based on PEG/polymer blends.
    Bley H; Fussnegger B; Bodmeier R
    Int J Pharm; 2010 May; 390(2):165-73. PubMed ID: 20132875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Solubilization of genistein in poly(oxyethylene) through eutectic crystal melting.
    Buddhiranon S; Kyu T
    J Phys Chem B; 2012 Jul; 116(27):7795-802. PubMed ID: 22702353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the phase behavior of polyethylene glycol 6000-itraconazole solid dispersions using DSC.
    Wang X; Michoel A; Van den Mooter G
    Int J Pharm; 2004 Mar; 272(1-2):181-7. PubMed ID: 15019081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relating solubility data of parabens in liquid PEG 400 to the behaviour of PEG 4000-parabens solid dispersions.
    Unga J; Tajarobi F; Norder O; Frenning G; Larsson A
    Eur J Pharm Biopharm; 2009 Oct; 73(2):260-8. PubMed ID: 19508891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of polyethylene glycol chain length on compatibility and release characteristics of ternary solid dispersions of itraconazole in polyethylene glycol/hydroxypropylmethylcellulose 2910 E5 blends.
    Janssens S; Denivelle S; Rombaut P; Van den Mooter G
    Eur J Pharm Sci; 2008 Oct; 35(3):203-10. PubMed ID: 18656535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: the eutectic microstructure.
    Law D; Wang W; Schmitt EA; Qiu Y; Krill SL; Fort JJ
    J Pharm Sci; 2003 Mar; 92(3):505-15. PubMed ID: 12587112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical characterization of nimodipine-polyethylene glycol solid dispersion systems.
    Barmpalexis P; Kachrimanis K; Georgarakis E
    Drug Dev Ind Pharm; 2014 Jul; 40(7):886-95. PubMed ID: 23611475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of crystallization behavior in drug/polyethylene glycol solid dispersions.
    Zhu Q; Harris MT; Taylor LS
    Mol Pharm; 2012 Mar; 9(3):546-53. PubMed ID: 22299821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microwave non-destructive testing technique for characterization of HPMC-PEG 3000 films.
    Wong TW; Deepak KG; Taib MN; Anuar NK
    Int J Pharm; 2007 Oct; 343(1-2):122-30. PubMed ID: 17597317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-resolved SAXS/WAXS study of the phase behavior and microstructural evolution of drug/PEG solid dispersions.
    Zhu Q; Harris MT; Taylor LS
    Mol Pharm; 2011 Jun; 8(3):932-9. PubMed ID: 21452866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding polymer-lipid solid dispersions--the properties of incorporated lipids govern the crystallisation behaviour of PEG.
    Unga J; Matsson P; Mahlin D
    Int J Pharm; 2010 Feb; 386(1-2):61-70. PubMed ID: 19900523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes.
    Ruan LP; Yu BY; Fu GM; Zhu DN
    J Pharm Biomed Anal; 2005 Jul; 38(3):457-64. PubMed ID: 15925247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions.
    Karavas E; Georgarakis E; Sigalas MP; Avgoustakis K; Bikiaris D
    Eur J Pharm Biopharm; 2007 Jun; 66(3):334-47. PubMed ID: 17267194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase behavior of poly(vinylpyrrolidone) containing amorphous solid dispersions in the presence of moisture.
    Rumondor AC; Marsac PJ; Stanford LA; Taylor LS
    Mol Pharm; 2009; 6(5):1492-505. PubMed ID: 19634917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid molecular dispersions of poorly water-soluble drugs in poly(2-hydroxyethyl methacrylate) hydrogels.
    Zahedi P; Lee PI
    Eur J Pharm Biopharm; 2007 Mar; 65(3):320-8. PubMed ID: 17182231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions between carbamazepine and polyethylene glycol (PEG) 6000: characterisations of the physical, solid dispersed and eutectic mixtures.
    Naima Z; Siro T; Juan-Manuel GD; Chantal C; René C; Jerome D
    Eur J Pharm Sci; 2001 Feb; 12(4):395-404. PubMed ID: 11231106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.